Condition
Neuropathic pain
2 compounds were checked against neuropathic pain, and every one of them earned a row.
Last updated
Recorded under Pain, alongside 1 other indication.
Compounds with a graded row
Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.
-
ARA-290
human RCT Direct outcome In registered trials
- Who was studied
- patients with sarcoidosis and symptoms of small-fibre neuropathy, n=22 (12 on ARA 290, 10 on placebo), 2 mg intravenously three times weekly for 4 weeks
A randomised, double-blind, placebo-controlled pilot trial measured the Small Fibre Neuropathy Screening List, the SF-36 pain dimension and the Brief Pain Inventory. SFNSL and the SF-36 pain dimension improved more on ARA 290 than on placebo, but Brief Pain Inventory scores fell equivalently in both arms, so the trial's general pain measure did not separate from placebo. The population is sarcoidosis-associated small-fibre neuropathy only, n=22; no trial in diabetic, chemotherapy-induced or post-herpetic neuropathy is on file, and ARA 290 has no regulatory approval anywhere.
Source PubMed Central 2 primary sources read for this row
-
PEA
human RCT Direct outcome Not approved for this condition
- Who was studied
- adults with type 1 or type 2 diabetes (62 of 65 type 2) and diabetic peripheral neuropathic pain confirmed by DN4 >4 or S-LANSS >12, n=66 analysed (33 palmitoylethanolamide, 33 placebo), mean age 63.5 years; 600 mg oral PEA daily (Levagen+ formulation) for 8 weeks
A single-centre, quadruple-blinded, randomised placebo-controlled trial measured the Brief Pain Inventory for Diabetic Peripheral Neuropathy and the Neuropathic Pain Symptom Inventory. BPI-DPN pain severity and pain interference both fell more on PEA than placebo (p <= 0.001), and most NPSI domains improved, but the evoked-pain domain reached only a trend (p = 0.09). The population is diabetic peripheral neuropathy alone; the wider PEA meta-analyses pool neuropathic with musculoskeletal and gynaecological pain and report no separate neuropathic subgroup estimate, and PEA is sold as a food supplement with no regulatory approval for neuropathic pain.
Source PubMed Central 3 primary sources read for this row
Every compound checked earned a row
Nothing was checked against neuropathic pain and set aside. That is unusual — most conditions here have a list at the bottom of this page.
What this page does not say
It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a row here is a record of a study rather than a reason to use anything. Every rung links to the rubric that assigned it.